重药控股
(000950)
| 流通市值：105.76亿 | | | 总市值：105.76亿 |
| 流通股本：17.28亿 | | | 总股本：17.28亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 20,432,336,918.06 | 82,447,409,172.78 | 62,211,401,881.27 | 41,188,217,331.84 |
| 营业收入 | 20,432,336,918.06 | 82,447,409,172.78 | 62,211,401,881.27 | 41,188,217,331.84 |
| 二、营业总成本 | 20,054,289,006.03 | 81,307,114,714.58 | 61,116,440,262.49 | 40,415,012,353.64 |
| 营业成本 | 19,032,002,171.74 | 76,507,072,951.45 | 57,722,565,015.73 | 38,177,845,488.73 |
| 税金及附加 | 48,347,169.04 | 202,914,256.36 | 144,014,156.18 | 95,633,246.59 |
| 销售费用 | 485,448,180.65 | 2,109,720,907.15 | 1,528,234,592.06 | 1,009,394,271.8 |
| 管理费用 | 326,570,075.33 | 1,748,854,423.19 | 1,163,604,488.01 | 752,371,295.81 |
| 研发费用 | 395,949.48 | 469,747.64 | 114,779.91 | 114,779.91 |
| 财务费用 | 161,525,459.79 | 738,082,428.79 | 557,907,230.6 | 379,653,270.8 |
| 其中:利息费用 | 162,500,623.19 | 758,261,522.73 | 586,844,710.86 | 399,397,135.84 |
| 其中:利息收入 | 7,212,435.71 | 60,990,139.31 | 51,046,224.71 | 36,129,431.83 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -43,645.49 | -3,068,104.51 | -861,030.74 | -861,030.74 |
| 加:投资收益 | 98,847,392.9 | 415,481,340.47 | 139,991,780.84 | 58,201,620.47 |
| 资产处置收益 | 523,085.48 | 4,629,873.82 | 1,831,874.32 | 1,202,756.45 |
| 资产减值损失(新) | 3,889,116.39 | -123,167,918.53 | -19,865,155.34 | -2,991,945.06 |
| 信用减值损失(新) | -247,479,387.46 | -786,150,760.54 | -572,285,350.1 | -374,439,753.39 |
| 其他收益 | 10,768,416.79 | 34,851,737.03 | 21,397,042.31 | 17,084,722.79 |
| 四、营业利润 | 244,552,890.64 | 682,870,625.94 | 665,170,780.07 | 471,401,348.72 |
| 加:营业外收入 | 2,560,981.11 | 14,417,463.26 | 7,803,703.27 | 6,406,692.87 |
| 减:营业外支出 | 1,833,198.05 | 25,428,551.5 | 15,538,263.58 | 10,563,402.91 |
| 五、利润总额 | 245,280,673.7 | 671,859,537.7 | 657,436,219.76 | 467,244,638.68 |
| 减:所得税费用 | 46,914,768.31 | 150,531,098.73 | 125,058,396.45 | 78,256,285.25 |
| 六、净利润 | 198,365,905.39 | 521,328,438.97 | 532,377,823.31 | 388,988,353.43 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 198,365,905.39 | 521,328,438.97 | 532,377,823.31 | 388,988,353.43 |
| 终止经营净利润 | - | 0 | - | - |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 170,729,724.08 | 386,715,159.31 | 384,010,323.39 | 282,265,967.39 |
| 少数股东损益 | 27,636,181.31 | 134,613,279.66 | 148,367,499.92 | 106,722,386.04 |
| 扣除非经常损益后的净利润 | 166,234,430.26 | 357,684,845.48 | 379,481,776.48 | 276,856,201.49 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.1 | 0.22 | 0.22 | 0.16 |
| (二)稀释每股收益 | 0.1 | 0.22 | 0.22 | 0.16 |
| 八、其他综合收益 | - | -2,590,237 | -7,482,030.39 | -13,831,098.39 |
| 归属于母公司股东的其他综合收益 | - | -3,607,425.12 | -7,540,554.64 | -13,889,622.64 |
| 九、综合收益总额 | 198,365,905.39 | 518,738,201.97 | 524,895,792.92 | 375,157,255.04 |
| 归属于母公司股东的综合收益总额 | 170,729,724.08 | 383,107,734.19 | 376,469,768.75 | 268,376,344.75 |
| 归属于少数股东的综合收益总额 | 27,636,181.31 | 135,630,467.78 | 148,426,024.17 | 106,780,910.29 |
| 公告日期 | 2026-04-24 | 2026-04-24 | 2025-10-28 | 2025-08-21 |
| 审计意见(境内) | | 标准无保留意见 | | |